Popularity Doesn’t Necessarily Make Prozac Best Antidepressant Choice

	Tweet

Although Prozac has achieved phenomenal marketing success, it may not be as effective as certain other antidepressants, according to a recent systematic review.

Researchers led by Andrea Cipriani, M.D., compared Prozac (fluoxetine) to other selective serotonin reuptake inhibitors, and to other antidepressants and found that Zoloft (sertraline) and Effexor (venlafaxine) were somewhat better for treating depression.

The review also compared the tolerability of fluoxetine and several other often-prescribed antidepressants. Patients found fluoxetine more tolerable than both Elavil or Endep (amitryptilline) and Tofranil (imipramine).

Cipriani, a psychiatrist at the University of Verona in Italy, said in an e-mail, “Fluoxetine, the most widely studied SSRI, has progressively replaced amitriptyline and imipramine as the standard of comparison for newer medications. We chose fluoxetine because of its long-time position as the market leader and because it has been often used as a reference compound for newer [antidepressants].”

Psychiatrist Xavier Amador, a member of the board of directors for the National Alliance for the Mentally Ill, said, “Prozac was available years before other SSRIs. Since, as a group, the SSRIs were far safer than [earlier antidepressants] the first one, Prozac, became hugely popular. It has tremendous name recognition for this reason.”

The review appeared in the latest issue of the Cochrane Library. The Cochrane Library is a publication of The Cochrane Collaboration, an independent international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The review pooled data from 132 published randomized controlled trials, with effectiveness data on 9,311 participants and of tolerability data on 14,391 participants, both inpatients and outpatients diagnosed with depression, without other ongoing medical problems.

The researchers looked at SSRIs, tricyclic and heterocyclic antidepressants, and newer antidepressants. The researchers analyzed participants’ scores on several diagnostic scales for depression, comparing measurements on Prozac with other antidepressants.

Results were mixed: Prozac was found less effective than Prothiaden (dothiepin), Zoloft, Remeron (mirtazapine) and Effexor but more effective than the antidepressants ABT-200 and milnacipran. Prozac was better tolerated than tricyclic antidepressants as a group and with other individual antidepressants.

“Although the better effectiveness profile of sertraline and venlafaxine over fluoxetine seems meaningful, it needs further investigation,” Cipriani said, noting that studies were short, usually eight weeks or less. “This limits the ability of the studies to show clinically meaningful differences,” he said. “We need more robust and pragmatic evidence, free from industry influence.”

According to Cipriani, fluoxetine’s huge success has occurred despite the fact that “results from randomized clinical trials did not clearly indicate that it offered substantial benefits over conventional agents.” Many studies have compared fluoxetine with other antidepressants, but he said a major problem with some of these studies is “that they have analyzed the SSRIs as a group and evidence applicable to this group of drugs might not be entirely applicable to fluoxetine alone.”

Until additional, robust, unbiased evidence becomes available, Cipriani said that clinicians ought to base their selection upon considerations of drug toxicity, patient acceptability and cost.

“The great majority of randomized controlled trials have been sponsored by pharmaceutical industry and data have shown a possible relationship between industry sponsorship and trial outcomes,” said Cipriani, “We need further analyses on the possible confounding role of sponsorship and new tools to improve the quality of evidence.”

The review notes that one of its co-authors has received fees for speaking and research grants from pharmaceutical companies that market antidepressants, and another has received funding and support from two companies that manufacture SSRIs.

# # #

Health Behavior News Service:
Cipriani A, et al. Fluoxetine versus other types of pharmacotherapy for depression (Review). The Cochrane Library 2005, Issue 4.

RELATED STORIES:
Anxiolytics: Choice of Medication   Prozac saves thousands of lives   Drug Approval Processes May Have Delayed Safety Warnings for Antidepressants   Antidepressants may affect fetus   Marijuana-like brain chemicals work as antidepressant   Anxiolytics:  Therapeutic Monitoring   Lexapro® curbs risk of recurrent depression   Daily Use of Antidepressants Associated With Increased Risk of Fracture in Older Adults   When one antidepressant fails, another may work   Antidepressants may pose risk to heart patients   Wellbutrin plus reward helps cocaine users cut back   New findings on antidepressants during pregnancy are reason for caution, not alarm   SSRIs and cardiovascular health   Mood Stabilizers in psychiatric practice   Anti-inflammatory drugs reduce effectiveness of SSRI antidepressants

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]